KR100999429B1 - 비만 치료 및 항산화 활성을 갖는 효모 가수분해물 - Google Patents
비만 치료 및 항산화 활성을 갖는 효모 가수분해물 Download PDFInfo
- Publication number
- KR100999429B1 KR100999429B1 KR1020100039717A KR20100039717A KR100999429B1 KR 100999429 B1 KR100999429 B1 KR 100999429B1 KR 1020100039717 A KR1020100039717 A KR 1020100039717A KR 20100039717 A KR20100039717 A KR 20100039717A KR 100999429 B1 KR100999429 B1 KR 100999429B1
- Authority
- KR
- South Korea
- Prior art keywords
- yeast
- obesity
- hydrolyzate
- group
- composition
- Prior art date
Links
- 240000004808 Saccharomyces cerevisiae Species 0.000 title claims abstract description 149
- 208000008589 Obesity Diseases 0.000 title claims abstract description 43
- 235000020824 obesity Nutrition 0.000 title claims abstract description 43
- 230000003078 antioxidant effect Effects 0.000 title claims description 20
- 239000000413 hydrolysate Substances 0.000 title abstract description 23
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 claims abstract description 148
- 239000000203 mixture Substances 0.000 claims abstract description 55
- 230000000694 effects Effects 0.000 claims abstract description 30
- 235000013305 food Nutrition 0.000 claims abstract description 25
- 239000004480 active ingredient Substances 0.000 claims abstract description 20
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 15
- 208000004611 Abdominal Obesity Diseases 0.000 claims abstract description 13
- 208000031226 Hyperlipidaemia Diseases 0.000 claims abstract description 8
- 206010065941 Central obesity Diseases 0.000 claims abstract description 7
- 231100000240 steatosis hepatitis Toxicity 0.000 claims abstract description 7
- 206010003210 Arteriosclerosis Diseases 0.000 claims abstract description 5
- 208000011775 arteriosclerosis disease Diseases 0.000 claims abstract description 5
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 9
- 238000009825 accumulation Methods 0.000 claims description 20
- 230000002401 inhibitory effect Effects 0.000 claims description 16
- 239000002537 cosmetic Substances 0.000 claims description 15
- 238000000034 method Methods 0.000 claims description 15
- 241001465754 Metazoa Species 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 8
- 230000004130 lipolysis Effects 0.000 claims description 7
- 208000004930 Fatty Liver Diseases 0.000 claims description 6
- 206010019708 Hepatic steatosis Diseases 0.000 claims description 6
- 208000010706 fatty liver disease Diseases 0.000 claims description 6
- 201000001320 Atherosclerosis Diseases 0.000 claims description 5
- 230000001225 therapeutic effect Effects 0.000 claims description 3
- 230000001737 promoting effect Effects 0.000 claims 4
- 230000000069 prophylactic effect Effects 0.000 claims 2
- 230000037396 body weight Effects 0.000 abstract description 8
- 230000003064 anti-oxidating effect Effects 0.000 abstract 1
- 230000007863 steatosis Effects 0.000 abstract 1
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 34
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 31
- 239000003925 fat Substances 0.000 description 24
- 235000019197 fats Nutrition 0.000 description 24
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
- 239000004365 Protease Substances 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 19
- 210000004369 blood Anatomy 0.000 description 18
- 239000008280 blood Substances 0.000 description 18
- 102000004190 Enzymes Human genes 0.000 description 17
- 108090000790 Enzymes Proteins 0.000 description 17
- 229940088598 enzyme Drugs 0.000 description 17
- 210000001789 adipocyte Anatomy 0.000 description 16
- 102000016267 Leptin Human genes 0.000 description 15
- 108010092277 Leptin Proteins 0.000 description 15
- 108091005804 Peptidases Proteins 0.000 description 15
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 15
- 208000021017 Weight Gain Diseases 0.000 description 15
- 229960003180 glutathione Drugs 0.000 description 15
- NRYBAZVQPHGZNS-ZSOCWYAHSA-N leptin Chemical compound O=C([C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CC(C)C)CCSC)N1CCC[C@H]1C(=O)NCC(=O)N[C@@H](CS)C(O)=O NRYBAZVQPHGZNS-ZSOCWYAHSA-N 0.000 description 15
- 229940039781 leptin Drugs 0.000 description 15
- -1 lipid peroxide Chemical class 0.000 description 15
- 235000019419 proteases Nutrition 0.000 description 15
- 235000019786 weight gain Nutrition 0.000 description 15
- 239000002609 medium Substances 0.000 description 14
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 13
- 241000700159 Rattus Species 0.000 description 13
- 229940118019 malondialdehyde Drugs 0.000 description 13
- 230000004584 weight gain Effects 0.000 description 13
- 210000000577 adipose tissue Anatomy 0.000 description 12
- 108090000623 proteins and genes Proteins 0.000 description 12
- 238000002835 absorbance Methods 0.000 description 11
- 235000011187 glycerol Nutrition 0.000 description 11
- 230000036541 health Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 102000004169 proteins and genes Human genes 0.000 description 11
- 150000003254 radicals Chemical class 0.000 description 11
- 241000282472 Canis lupus familiaris Species 0.000 description 10
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 235000012000 cholesterol Nutrition 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 150000002632 lipids Chemical class 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- 239000000523 sample Substances 0.000 description 9
- 101710180012 Protease 7 Proteins 0.000 description 8
- 230000002292 Radical scavenging effect Effects 0.000 description 8
- 238000011084 recovery Methods 0.000 description 8
- 239000000725 suspension Substances 0.000 description 8
- 230000004580 weight loss Effects 0.000 description 8
- 239000006071 cream Substances 0.000 description 7
- 235000014113 dietary fatty acids Nutrition 0.000 description 7
- 201000010099 disease Diseases 0.000 description 7
- 239000000194 fatty acid Substances 0.000 description 7
- 229930195729 fatty acid Natural products 0.000 description 7
- 235000009200 high fat diet Nutrition 0.000 description 7
- 210000004185 liver Anatomy 0.000 description 7
- 239000001301 oxygen Substances 0.000 description 7
- 229910052760 oxygen Inorganic materials 0.000 description 7
- 108010024636 Glutathione Proteins 0.000 description 6
- 108010053070 Glutathione Disulfide Proteins 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- OHDRQQURAXLVGJ-HLVWOLMTSA-N azane;(2e)-3-ethyl-2-[(e)-(3-ethyl-6-sulfo-1,3-benzothiazol-2-ylidene)hydrazinylidene]-1,3-benzothiazole-6-sulfonic acid Chemical compound [NH4+].[NH4+].S/1C2=CC(S([O-])(=O)=O)=CC=C2N(CC)C\1=N/N=C1/SC2=CC(S([O-])(=O)=O)=CC=C2N1CC OHDRQQURAXLVGJ-HLVWOLMTSA-N 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 235000005911 diet Nutrition 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- YPZRWBKMTBYPTK-BJDJZHNGSA-N glutathione disulfide Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@H](C(=O)NCC(O)=O)CSSC[C@@H](C(=O)NCC(O)=O)NC(=O)CC[C@H](N)C(O)=O YPZRWBKMTBYPTK-BJDJZHNGSA-N 0.000 description 6
- 230000003647 oxidation Effects 0.000 description 6
- 238000007254 oxidation reaction Methods 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 108090000526 Papain Proteins 0.000 description 5
- 241000235070 Saccharomyces Species 0.000 description 5
- 230000003187 abdominal effect Effects 0.000 description 5
- 238000005119 centrifugation Methods 0.000 description 5
- 239000000306 component Substances 0.000 description 5
- 235000018823 dietary intake Nutrition 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 230000004792 oxidative damage Effects 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 239000006228 supernatant Substances 0.000 description 5
- 150000003626 triacylglycerols Chemical class 0.000 description 5
- 241000194110 Bacillus sp. (in: Bacteria) Species 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 4
- 108010023302 HDL Cholesterol Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000006011 Stroke Diseases 0.000 description 4
- 230000003579 anti-obesity Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000037213 diet Effects 0.000 description 4
- HHEAADYXPMHMCT-UHFFFAOYSA-N dpph Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1[N]N(C=1C=CC=CC=1)C1=CC=CC=C1 HHEAADYXPMHMCT-UHFFFAOYSA-N 0.000 description 4
- 150000004665 fatty acids Chemical class 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000007935 neutral effect Effects 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 235000019834 papain Nutrition 0.000 description 4
- 229940055729 papain Drugs 0.000 description 4
- 230000028327 secretion Effects 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 108010088751 Albumins Proteins 0.000 description 3
- 102000009027 Albumins Human genes 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 208000005189 Embolism Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 102000006587 Glutathione peroxidase Human genes 0.000 description 3
- 108700016172 Glutathione peroxidases Proteins 0.000 description 3
- 102000001554 Hemoglobins Human genes 0.000 description 3
- 108010054147 Hemoglobins Proteins 0.000 description 3
- 108010009736 Protein Hydrolysates Proteins 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 208000007536 Thrombosis Diseases 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000003833 cell viability Effects 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 239000000839 emulsion Substances 0.000 description 3
- 210000003743 erythrocyte Anatomy 0.000 description 3
- 235000021050 feed intake Nutrition 0.000 description 3
- 235000013376 functional food Nutrition 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 238000011534 incubation Methods 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 2
- 244000063299 Bacillus subtilis Species 0.000 description 2
- 235000014469 Bacillus subtilis Nutrition 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 208000002177 Cataract Diseases 0.000 description 2
- 206010008132 Cerebral thrombosis Diseases 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 239000004606 Fillers/Extenders Substances 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 108010010234 HDL Lipoproteins Proteins 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 206010020751 Hypersensitivity Diseases 0.000 description 2
- 102000004877 Insulin Human genes 0.000 description 2
- 108090001061 Insulin Proteins 0.000 description 2
- 201000001429 Intracranial Thrombosis Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 206010029098 Neoplasm skin Diseases 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 241000286209 Phasianidae Species 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000000453 Skin Neoplasms Diseases 0.000 description 2
- BGNXCDMCOKJUMV-UHFFFAOYSA-N Tert-Butylhydroquinone Chemical compound CC(C)(C)C1=CC(O)=CC=C1O BGNXCDMCOKJUMV-UHFFFAOYSA-N 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 230000007815 allergy Effects 0.000 description 2
- 150000001413 amino acids Chemical group 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 239000000440 bentonite Substances 0.000 description 2
- 229910000278 bentonite Inorganic materials 0.000 description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000017531 blood circulation Effects 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000005779 cell damage Effects 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 210000000028 corpus adiposum pararenale Anatomy 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000008260 defense mechanism Effects 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- MGJZITXUQXWAKY-UHFFFAOYSA-N diphenyl-(2,4,6-trinitrophenyl)iminoazanium Chemical compound [O-][N+](=O)C1=CC([N+](=O)[O-])=CC([N+]([O-])=O)=C1N=[N+](C=1C=CC=CC=1)C1=CC=CC=C1 MGJZITXUQXWAKY-UHFFFAOYSA-N 0.000 description 2
- 239000007884 disintegrant Substances 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 201000010063 epididymitis Diseases 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 239000007902 hard capsule Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 229940125396 insulin Drugs 0.000 description 2
- 244000144972 livestock Species 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 235000019198 oils Nutrition 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 244000144977 poultry Species 0.000 description 2
- 235000013594 poultry meat Nutrition 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000013587 production medium Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000007901 soft capsule Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- 239000000375 suspending agent Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 230000037221 weight management Effects 0.000 description 2
- 235000020138 yakult Nutrition 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 1
- LQWJXPAFEKEYGT-GEMLJDPKSA-N (2s)-2-amino-5-[[(2r)-1-(carboxymethylamino)-1-oxo-3-sulfanylpropan-2-yl]amino]-5-oxopentanoic acid;sulfuric acid Chemical compound OS(O)(=O)=O.OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O LQWJXPAFEKEYGT-GEMLJDPKSA-N 0.000 description 1
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical class CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 1
- WXHLLJAMBQLULT-UHFFFAOYSA-N 2-[[6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-yl]amino]-n-(2-methyl-6-sulfanylphenyl)-1,3-thiazole-5-carboxamide;hydrate Chemical compound O.C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1S WXHLLJAMBQLULT-UHFFFAOYSA-N 0.000 description 1
- SLAMLWHELXOEJZ-UHFFFAOYSA-N 2-nitrobenzoic acid Chemical compound OC(=O)C1=CC=CC=C1[N+]([O-])=O SLAMLWHELXOEJZ-UHFFFAOYSA-N 0.000 description 1
- RVBUGGBMJDPOST-UHFFFAOYSA-N 2-thiobarbituric acid Chemical compound O=C1CC(=O)NC(=S)N1 RVBUGGBMJDPOST-UHFFFAOYSA-N 0.000 description 1
- KIUMMUBSPKGMOY-UHFFFAOYSA-N 3,3'-Dithiobis(6-nitrobenzoic acid) Chemical compound C1=C([N+]([O-])=O)C(C(=O)O)=CC(SSC=2C=C(C(=CC=2)[N+]([O-])=O)C(O)=O)=C1 KIUMMUBSPKGMOY-UHFFFAOYSA-N 0.000 description 1
- AGNTUZCMJBTHOG-UHFFFAOYSA-N 3-[3-(2,3-dihydroxypropoxy)-2-hydroxypropoxy]propane-1,2-diol Chemical compound OCC(O)COCC(O)COCC(O)CO AGNTUZCMJBTHOG-UHFFFAOYSA-N 0.000 description 1
- WGTSSIAUHVVZGA-UHFFFAOYSA-N 4-[4-(dimethylamino)phenyl]-N,N-dimethylaniline dihydrochloride Chemical compound Cl.Cl.CN(C1=CC=C(C2=CC=C(N(C)C)C=C2)C=C1)C WGTSSIAUHVVZGA-UHFFFAOYSA-N 0.000 description 1
- WIGIZIANZCJQQY-UHFFFAOYSA-N 4-ethyl-3-methyl-N-[2-[4-[[[(4-methylcyclohexyl)amino]-oxomethyl]sulfamoyl]phenyl]ethyl]-5-oxo-2H-pyrrole-1-carboxamide Chemical compound O=C1C(CC)=C(C)CN1C(=O)NCCC1=CC=C(S(=O)(=O)NC(=O)NC2CCC(C)CC2)C=C1 WIGIZIANZCJQQY-UHFFFAOYSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 102100036475 Alanine aminotransferase 1 Human genes 0.000 description 1
- 108010082126 Alanine transaminase Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- 241000726096 Aratinga Species 0.000 description 1
- 240000006439 Aspergillus oryzae Species 0.000 description 1
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 1
- 241000228257 Aspergillus sp. Species 0.000 description 1
- 206010003645 Atopy Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 241000193830 Bacillus <bacterium> Species 0.000 description 1
- 241001037822 Bacillus bacterium Species 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108010004032 Bromelains Proteins 0.000 description 1
- 206010007269 Carcinogenicity Diseases 0.000 description 1
- 240000006432 Carica papaya Species 0.000 description 1
- 235000009467 Carica papaya Nutrition 0.000 description 1
- 108010053835 Catalase Proteins 0.000 description 1
- 108030002440 Catalase peroxidases Proteins 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 239000004470 DL Methionine Substances 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283074 Equus asinus Species 0.000 description 1
- 241001331845 Equus asinus x caballus Species 0.000 description 1
- 108090000270 Ficain Proteins 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 108010063907 Glutathione Reductase Proteins 0.000 description 1
- 102100036442 Glutathione reductase, mitochondrial Human genes 0.000 description 1
- 102000004157 Hydrolases Human genes 0.000 description 1
- 108090000604 Hydrolases Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 206010067125 Liver injury Diseases 0.000 description 1
- 239000006137 Luria-Bertani broth Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 101710118538 Protease Proteins 0.000 description 1
- 241000287530 Psittaciformes Species 0.000 description 1
- 244000088415 Raphanus sativus Species 0.000 description 1
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 description 1
- 241000235072 Saccharomyces bayanus Species 0.000 description 1
- 235000003534 Saccharomyces carlsbergensis Nutrition 0.000 description 1
- 241000877401 Saccharomyces ellipsoideus Species 0.000 description 1
- 241001123227 Saccharomyces pastorianus Species 0.000 description 1
- 241000287231 Serinus Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- ULUAUXLGCMPNKK-UHFFFAOYSA-N Sulfobutanedioic acid Chemical compound OC(=O)CC(C(O)=O)S(O)(=O)=O ULUAUXLGCMPNKK-UHFFFAOYSA-N 0.000 description 1
- 241000282898 Sus scrofa Species 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 244000288561 Torulaspora delbrueckii Species 0.000 description 1
- 235000014681 Torulaspora delbrueckii Nutrition 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 description 1
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 239000011149 active material Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 239000003674 animal food additive Substances 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 235000021052 average daily weight gain Nutrition 0.000 description 1
- 235000021053 average weight gain Nutrition 0.000 description 1
- OIJMIQIDIZASII-UHFFFAOYSA-N benzene;benzoic acid Chemical compound C1=CC=CC=C1.OC(=O)C1=CC=CC=C1 OIJMIQIDIZASII-UHFFFAOYSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000012503 blood component Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019835 bromelain Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 231100000260 carcinogenicity Toxicity 0.000 description 1
- 230000007670 carcinogenicity Effects 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000000593 degrading effect Effects 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 235000007882 dietary composition Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 239000012470 diluted sample Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000000062 effect on obesity Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000012091 fetal bovine serum Substances 0.000 description 1
- 235000019836 ficin Nutrition 0.000 description 1
- POTUGHMKJGOKRI-UHFFFAOYSA-N ficin Chemical compound FI=CI=N POTUGHMKJGOKRI-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 150000002314 glycerols Chemical class 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 231100000234 hepatic damage Toxicity 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 210000003016 hypothalamus Anatomy 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical class C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 230000008818 liver damage Effects 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 230000006371 metabolic abnormality Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N methionine Chemical compound CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 235000006109 methionine Nutrition 0.000 description 1
- 108010009355 microbial metalloproteinases Proteins 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000013379 molasses Nutrition 0.000 description 1
- CQDGTJPVBWZJAZ-UHFFFAOYSA-N monoethyl carbonate Chemical compound CCOC(O)=O CQDGTJPVBWZJAZ-UHFFFAOYSA-N 0.000 description 1
- 230000007886 mutagenicity Effects 0.000 description 1
- 231100000299 mutagenicity Toxicity 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 150000005830 nonesterified fatty acids Chemical class 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000036542 oxidative stress Effects 0.000 description 1
- YPZRWBKMTBYPTK-UHFFFAOYSA-N oxidized gamma-L-glutamyl-L-cysteinylglycine Natural products OC(=O)C(N)CCC(=O)NC(C(=O)NCC(O)=O)CSSCC(C(=O)NCC(O)=O)NC(=O)CCC(N)C(O)=O YPZRWBKMTBYPTK-UHFFFAOYSA-N 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000008055 phosphate buffer solution Substances 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- USHAGKDGDHPEEY-UHFFFAOYSA-L potassium persulfate Chemical compound [K+].[K+].[O-]S(=O)(=O)OOS([O-])(=O)=O USHAGKDGDHPEEY-UHFFFAOYSA-L 0.000 description 1
- 210000000229 preadipocyte Anatomy 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 235000019624 protein content Nutrition 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 235000021067 refined food Nutrition 0.000 description 1
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 1
- 229940071089 sarcosinate Drugs 0.000 description 1
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000020183 skimmed milk Nutrition 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000012086 standard solution Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000004250 tert-Butylhydroquinone Substances 0.000 description 1
- 235000019281 tert-butylhydroquinone Nutrition 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 235000018648 unbalanced nutrition Nutrition 0.000 description 1
- 229940116269 uric acid Drugs 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/062—Ascomycota
- A61K36/064—Saccharomycetales, e.g. baker's yeast
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/18—Antioxidants, e.g. antiradicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Botany (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Fodder In General (AREA)
Abstract
Description
도 2는 효모 가수분해물이 3T3-L1 지방세포의 글리세롤 및 렙틴 분비량에 미치는 영향을 나타낸다.
도 3은 MTT 방법으로 측정한, 3T3-L1 지방세포주에 대한 효모 가수분해물의 세포 독성을 보여준다.
도 4는 효모 KH-15 가수분해물의 래트의 DPPH 및 ABTS라디칼 소거능을 나타낸다.
도 5는 효모 KH-15 가수분해물이 SD 래트의 체중에 미치는 영향을 보여준다.
도 6은 효모 KH-15 가수분해물이 SD 래트의 지방 축적을 억제하는 효과를 나타낸다.
도 7은 효모 KH-15 가수분해물이 개의 체중에 미치는 영향을 보여준다.
도 8은 효모 KH-15 가수분해물이 개의 복부 둘레에 미치는 영향을 나타낸다.
도 9는 효모 KH-15 가수분해물 투여 시, 개의 혈액 내의 MDA 및 GSH 함량을 나타낸다.
효소 | source | 최적 조건 | 분류 | |
온도(℃) | pH | |||
Protamax | Bacillus sp. | 35-60 | 6.6-7.5 | Complex |
Flavourzyme | Aspergillus sp. | 45-50 | 5.0-7.0 | complex |
Proleather | Bacillus sp. | 60 | 10 | Endo |
Protease A | Aspergillus oryzae | 50 | 7.0 | Exo |
Aroase AP-10 | Bacillus subtilis | 50-55 | 7.0-8.0 | - |
Pescalase | Bacillus subtilis | 60 | 8.0 | Endo |
Papain | Carica papaya | 50 | 6.5 | complex |
효소 | 프로타맥스 | 플라보자임 | 프로리테르 | 프로테아제 A | 에이로즈 | 피스칼레이즈 | KH-15 | 파파인 |
단백질 회수율(%) | 52.3±3.2 | 54.5±4.5 | 46.7±4.7 | 44.5±5.4 | 48.9±8.9 | 50.4±5.0 | 53.9±5.0 | 51.3±2.4 |
대조군 |
프로타맥스 |
플라보자임 |
프로리테르 |
|
글리세롤 (%) |
100.0±3.5 |
109.3±3.9 |
114.5±4.1 |
100.4±5.3 |
렙틴 (%) |
100.0±2.7 |
58.7±5.8 |
35.7±3.7 |
90.6±4.5 |
프로테아제 A |
에이로즈 |
피스칼레이즈 |
KH -15 |
파파인 |
99.8±3.3 |
105.4±4.3 |
103.5±3.4 |
121.8±2.8 |
101.1±1.5 |
89.7±2.7 |
75.9±4.3 |
65.8±5.8 |
23.5±3.5 |
93.3±5.3 |
농도 (㎍/mL) | 대조군 | 프로타맥스 | 플라보자임 | 프로리테르 |
50 | 100.0±3.3 | 108.4±4.8 | 106.4±2.4 | 98.9±3.1 |
100 | 112.5±2.5 | 111.4±4.1 | 106.5±5.6 | |
프로테아제 A | 에이로즈 | 피스칼레이즈 | KH -15 | 파파인 |
99.7±3.8 | 102.3±3.2 | 100.5±5.0 | 104.3±4.3 | 103.2±3.5 |
104.5±5.4 | 109.6±6.9 | 110.3±3.1 | 115.6±3.5 | 110.5±3.4 |
Nutrient | 고지방 식이(g/100g diet ) |
Casein | 20 |
Corn starch | 32.3 |
Sucrose | 10 |
Lard | 20 |
Soybean oil | 10 |
Mineral mixture1 | 3.5 |
Vitamine mixture2 | 1 |
Cellulose | 3 |
DL-methionine | 0.2 |
Total energy(kcal) | 519.2 |
Percent of calories ( per total energy ) | |
Fat | 52 |
Carbohydrate | 32.6 |
Protein | 15.4 |
Group | 중성지방 (mg/dl) | 총 콜레스테롤(mg/dl) | HDL 콜레스테롤(mg/dl) | HTR |
대조군 | 96.28 ± 11.31 | 102.45 ± 4.94 | 56.42 ± 2.62 | 0.58 ± 0.04 |
효모 KH-15 가수분해물 투여군 | 80.07 ± 9.98 | 86.87 ± 5.11* | 75.70 ± 2.79** | 0.85 ± 0.04** |
Group | MDA | GSH | |
Liver (μmol/g) | Serum (μmol/mL) | Liver (mmol/g) | |
대조군 | 12.0±3.7b | 253.3±52.1b | 4.6±0.9b |
효모 KH-15 가수분해물 투여군 | 9.0±1.7a | 437.4±223.7a | 6.7±1.2a |
Group | 식이 섭취량(g/day) | 체중 증가량(g/day) | 식이효율 |
대조군 | 17.36±0.46 | 7.28±0.76 | 0.42±0.04 |
효모 KH-15 가수분해물 투여군 | 17.21±0.60 | 5.63±0.63 | 0.33±0.04 |
그룹 | 1일차-10일차 | 11일차-20일차 | 21일차-30일차 |
대조군 | 표준사료 | 표준사료 | 표준사료 |
실험군 1 (Eatless-A) |
표준사료+효모 KH-15 가수분해물 | 표준사료+ 효모 KH-15 가수분해물 | 표준사료+ 효모 KH-15 가수분해물 |
실험군 2 (Eatless-B) |
표준사료 | 표준사료+ 효모 KH-15 가수분해물 | 표준사료 |
지표 | 대조군 | 실험군 1 | 실험군 2 | 정상 범위 |
적혈구(1012/L) | 6.0±0.1 | 5.8±0.3 | 6.3±0.2 | 4.7-7.1 |
백혈구(109/L) | 7.2±0.4 | 8.3±0.4 | 7.9±0.4 | 5-12 |
헤모글로빈(g/100 mL) | 13.0±0.7 | 13.5±0.45 | 12.7±0.6 | 9-15 |
지표 | 대조군 | 실험군 1 | 실험군 2 | 정상 범위 |
총 콜레스테롤(mmol/L) | 3.68±0.8 | 3.41±0.78 | 3.54±0.43 | 3.5-7.25 |
총 단백질 (g/L) | 54.6±2.1 | 56.8±1.8 | 53.8±1.2 | 50-62 |
알부민(g/L) | 32.1±0.9 | 31.5±1.4 | 30.8±2.1 | 27-38 |
글로뷸린(g/L) | 22.3±2.1 | 25.7±0.9 | 24.6±1.6 | 17-30 |
Alanine aminotransferase (U/L) |
28.0±4.5 | 34.5±2.7 | 36.7±3.5 | 0-77 |
Alkaline phosphatase (U/L) | 90.4±8.9 | 99.5±5.6 | 100.2±6.2 | 0-174 |
Claims (11)
- 서열번호 1의 아미노산 서열을 포함하는 KH-15의 효모(Saccharomyces cerevisiae) 가수분해물을 유효성분으로 포함하며, 지방 분해 촉진 및 지방 축적 저해 활성을 갖는 비만 개선 및 예방용 식품 조성물.
- 서열번호 1의 아미노산 서열을 포함하는 KH-15의 효모(Saccharomyces cerevisiae) 가수분해물을 유효성분으로 포함하며, 지방 분해 촉진 및 지방 축적 저해 활성을 갖는 비만 개선 및 예방용 사료 조성물.
- 서열번호 1의 아미노산 서열을 포함하는 KH-15의 효모(Saccharomyces cerevisiae) 가수분해물을 유효성분으로 포함하며, 항산화 활성을 갖는 화장료 조성물.
- 서열번호 1의 아미노산 서열을 포함하는 KH-15의 효모(Saccharomyces cerevisiae) 가수분해물을 유효성분으로 포함하며, 지방 분해 촉진 및 지방 축적 저해 활성을 갖는, 동맥경화, 내장비만, 복부비만, 고지혈증, 지방간 및 비만으로 구성된 군으로부터 선택되는 어느 하나의 예방 및 치료용 약학적 조성물.
- 제 2항의 사료 조성물을 동물에 투여하는 단계를 포함하는 동물의 비만 개선 및 예방 방법.
- 제 4항의 약학적 조성물을 동물에 투여하는 단계를 포함하는, 동물의 동맥경화, 내장비만, 복부비만, 고지혈증, 지방간 및 비만으로 구성된 군으로부터 선택되는 어느 하나를 예방 또는 치료하는 방법.
- 효모(Saccharomyces cerevisiae)에 서열번호 1의 아미노산 서열을 포함하는 KH-15를 처리하는 단계를 포함하는, 지방 분해 촉진 및 지방 축적 저해 활성을 갖는 비만 개선 및 예방용 식품 조성물의 제조 방법.
- 효모(Saccharomyces cerevisiae)에 서열번호 1의 아미노산 서열을 포함하는 KH-15를 처리하는 단계를 포함하는, 지방 분해 촉진 및 지방 축적 저해 활성을 갖는 비만 개선 및 예방용 사료 조성물의 제조 방법.
- 효모(Saccharomyces cerevisiae)에 서열번호 1의 아미노산 서열을 포함하는 KH-15를 처리하는 단계를 포함하는, 항산화 활성을 갖는 화장료 조성물의 제조 방법.
- 효모(Saccharomyces cerevisiae)에 서열번호 1의 아미노산 서열을 포함하는 KH-15를 처리하는 단계를 포함하는, 지방 분해 촉진 및 지방 축적 저해 활성을 갖는, 동맥경화, 내장비만, 복부비만, 고지혈증, 지방간 및 비만으로 구성된 군으로부터 선택되는 어느 하나의 예방 및 치료용 약학적 조성물의 제조 방법.
- 삭제
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100039717A KR100999429B1 (ko) | 2010-04-28 | 2010-04-28 | 비만 치료 및 항산화 활성을 갖는 효모 가수분해물 |
JP2010233127A JP5902382B2 (ja) | 2010-04-28 | 2010-10-15 | 肥満治療効果及び抗酸化活性を有する酵母加水分解物を含む組成物及びその製造方法 |
PCT/KR2011/003116 WO2011136573A2 (ko) | 2010-04-28 | 2011-04-27 | 비만 치료 및 항산화 활성을 갖는 효모 가수분해물 |
US13/643,870 US20130052185A1 (en) | 2010-04-28 | 2011-04-27 | Yeast hydrolysate having obesity treatment effects and antioxidant activity |
EP11775278.2A EP2564860B1 (en) | 2010-04-28 | 2011-04-27 | Yeast hydrolysate having obesity treatment effects and antioxidant activity |
JP2016046918A JP2016147881A (ja) | 2010-04-28 | 2016-03-10 | 肥満治療効果及び抗酸化活性を有する酵母加水分解物を含む組成物及びその製造方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020100039717A KR100999429B1 (ko) | 2010-04-28 | 2010-04-28 | 비만 치료 및 항산화 활성을 갖는 효모 가수분해물 |
Publications (1)
Publication Number | Publication Date |
---|---|
KR100999429B1 true KR100999429B1 (ko) | 2010-12-09 |
Family
ID=43512550
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020100039717A KR100999429B1 (ko) | 2010-04-28 | 2010-04-28 | 비만 치료 및 항산화 활성을 갖는 효모 가수분해물 |
Country Status (5)
Country | Link |
---|---|
US (1) | US20130052185A1 (ko) |
EP (1) | EP2564860B1 (ko) |
JP (2) | JP5902382B2 (ko) |
KR (1) | KR100999429B1 (ko) |
WO (1) | WO2011136573A2 (ko) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024002150A1 (en) * | 2022-06-29 | 2024-01-04 | Microbiota I - Center (Magic) Limited | Methods and compositions for treating obesity using microorganisms |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100999429B1 (ko) * | 2010-04-28 | 2010-12-09 | (주)네오크레마 | 비만 치료 및 항산화 활성을 갖는 효모 가수분해물 |
SG11201406711TA (en) | 2012-04-18 | 2014-11-27 | Solazyme Inc | Tailored oils |
KR101372526B1 (ko) * | 2012-05-31 | 2014-03-11 | 고려대학교 산학협력단 | 효모 가수분해물을 포함하는 체지방 감소 및 근력 강화용 조성물 |
KR101272606B1 (ko) | 2013-03-15 | 2013-06-07 | (주)에쎄르 | 식욕억제와 체중 감량, 지방 축적 억제의 효과를 갖는 효모 가수분해물과 이를 포함하는 식품 및 그 제조 방법 |
WO2017173241A1 (en) | 2016-03-31 | 2017-10-05 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
AU2017240068B2 (en) | 2016-03-31 | 2022-12-15 | Gojo Industries, Inc. | Antimicrobial peptide stimulating cleansing composition |
CA3043748A1 (en) | 2016-11-23 | 2018-05-31 | Gojo Industries, Inc. | Sanitizer composition with probiotic/prebiotic active ingredient |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH08100175A (ja) * | 1994-09-30 | 1996-04-16 | Kohjin Co Ltd | 水溶性の酵母タンパク質分解物 |
JPH0956361A (ja) * | 1995-06-15 | 1997-03-04 | Kirin Brewery Co Ltd | 酵母エキスの製造方法 |
JPH10203994A (ja) * | 1997-01-27 | 1998-08-04 | Ichimaru Pharcos Co Ltd | 生理活性作用組成物 |
JP3930808B2 (ja) * | 2001-02-27 | 2007-06-13 | ニューロタイド カンパニー リミテッド | 抗ストレス機能、抗疲労機能、月経前期症候群及び月経痛緩和機能及び脳神経栄養因子としての機能を有する酵母由来機能性ペプチド及びその製造方法 |
KR100612197B1 (ko) * | 2004-05-28 | 2006-08-11 | (주)뉴로타이드 | 선택적 세로토닌 및 노르에피네프린의 재흡수 억제능을갖는 효모 추출물 |
FR2825004B1 (fr) * | 2001-05-22 | 2005-02-11 | Bio Springer | Produit dietetique satiant |
KR20040097813A (ko) * | 2003-05-13 | 2004-11-18 | (주)뉴로타이드 | 식욕억제, 체지방 감소 및 배변 활성화등 3가지 기능을 갖는 항비만 기능성 조성물 |
KR20050116850A (ko) * | 2004-06-08 | 2005-12-13 | 학교법인 영광학원 | 신규 바실러스 속 미생물 및 이를 이용하여 제조된 기능성된장 |
US8252314B2 (en) * | 2004-09-24 | 2012-08-28 | Hill's Pet Nutrition, Inc. | Hypoallergenic composition |
JP2007049989A (ja) * | 2005-07-20 | 2007-03-01 | Nippon Paper Chemicals Co Ltd | 酵母エキス及びその製造方法 |
JP5025491B2 (ja) * | 2006-01-13 | 2012-09-12 | 株式会社明治 | 抗炎症組成物および抗炎症組成物の製造法 |
JP4450821B2 (ja) * | 2006-04-06 | 2010-04-14 | 株式会社山田養蜂場本社 | 低アレルゲン化ローヤルゼリーの製造方法 |
KR100856799B1 (ko) * | 2007-11-12 | 2008-09-05 | (주)새롬바이오 | 효모 가수분해물을 유효성분으로 함유하는, 성장촉진 효과를 갖는 조성물 및 이를 포함하는 식품 |
KR100999429B1 (ko) * | 2010-04-28 | 2010-12-09 | (주)네오크레마 | 비만 치료 및 항산화 활성을 갖는 효모 가수분해물 |
-
2010
- 2010-04-28 KR KR1020100039717A patent/KR100999429B1/ko active IP Right Grant
- 2010-10-15 JP JP2010233127A patent/JP5902382B2/ja active Active
-
2011
- 2011-04-27 US US13/643,870 patent/US20130052185A1/en not_active Abandoned
- 2011-04-27 WO PCT/KR2011/003116 patent/WO2011136573A2/ko active Application Filing
- 2011-04-27 EP EP11775278.2A patent/EP2564860B1/en active Active
-
2016
- 2016-03-10 JP JP2016046918A patent/JP2016147881A/ja active Pending
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2024002150A1 (en) * | 2022-06-29 | 2024-01-04 | Microbiota I - Center (Magic) Limited | Methods and compositions for treating obesity using microorganisms |
Also Published As
Publication number | Publication date |
---|---|
US20130052185A1 (en) | 2013-02-28 |
EP2564860A4 (en) | 2014-01-08 |
JP2011231097A (ja) | 2011-11-17 |
JP5902382B2 (ja) | 2016-04-13 |
JP2016147881A (ja) | 2016-08-18 |
EP2564860B1 (en) | 2015-03-04 |
EP2564860A2 (en) | 2013-03-06 |
WO2011136573A2 (ko) | 2011-11-03 |
WO2011136573A3 (ko) | 2012-04-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100999429B1 (ko) | 비만 치료 및 항산화 활성을 갖는 효모 가수분해물 | |
Cherng et al. | Preventing dyslipidemia by Chlorella pyrenoidosa in rats and hamsters after chronic high fat diet treatment | |
JP5718917B2 (ja) | 新規なラクトバチルス・プランタラム及びこれを含む組成物 | |
JP5985138B2 (ja) | エネルギー消費促進剤 | |
Yang et al. | Effects of chicken-liver hydrolysates on lipid metabolism in a high-fat diet | |
Melliou et al. | Chemistry and bioactivities of royal jelly | |
AU2017337936B2 (en) | Novel Lactobacillus Sakei And Composition Comprising The Same | |
MX2008012874A (es) | Formulaciones alimenticias que contienen acido docosahexaenoico. | |
JP2012516842A (ja) | 代謝症候群の抑制のためのスファランサス・インディクスおよびガルシニア・マンゴスターナ由来の組成物 | |
KR20130140215A (ko) | 펩티드 | |
KR20210062660A (ko) | 노화, 근육, 뼈, 장, 고지혈증, 피부 및 뇌를 위한 프로바이오틱 균주 | |
JP2009029710A (ja) | 抗酸化剤、抗老化剤、抗炎症剤、育毛剤、抗肥満剤、及びエンドセリン−1mRNA発現上昇抑制剤、並びに化粧料及び美容用飲食品 | |
KR20190003304A (ko) | 쌍별귀뚜라미 추출물을 유효성분으로 포함하는 지방간 질환의 예방, 개선 또는 치료용 조성물 | |
JP6049381B2 (ja) | 養蜂産品を含むグネツム組成物 | |
JP2022169385A (ja) | タモギタケ又はその処理物を有効成分として含む、脂質代謝改善剤 | |
Sivamaruthi et al. | A comprehensive review on functional properties of fermented rice bran | |
RU2713656C2 (ru) | СПОСОБЫ ЛЕЧЕНИЯ ДИСРЕГУЛЯЦИИ ЯДЕРНОГО ФАКТОРА КОРОТКОЦЕПОЧЕЧНОГО ЭНХЕНСЕРА КАППА АКТИВИРОВАННОЙ КЛЕТКИ В (NF-κB) В ОРГАНИЗМЕ, НУЖДАЮЩЕМСЯ В ЭТОМ, С ИСПОЛЬЗОВАНИЕМ КОМПОЗИЦИЙ МЕМБРАН ЯИЧНОЙ СКОРЛУПЫ | |
RU2567053C2 (ru) | Состав, ускоряющий продукцию адипонектина | |
US20230040395A1 (en) | Composition for suppressing obesity | |
JP7344661B2 (ja) | 食品組成物の製造方法 | |
JP7101363B2 (ja) | セレノネイン含有組成物 | |
WO2007034958A1 (ja) | 穀類由来の成分を有効成分とする血管新生阻害の作用を有する組成物 | |
KR102687978B1 (ko) | 땅콩 겉껍질 추출물을 포함하는 비만의 개선, 예방 또는 치료용 조성물 | |
Abdel-Atty et al. | Biological and Biochemical Effect of Green Peas and Lentils Sprouts on Rats with Fatty Liver | |
JP7206623B2 (ja) | 糖代謝異常の予防および改善用組成物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
A302 | Request for accelerated examination | ||
E902 | Notification of reason for refusal | ||
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant | ||
FPAY | Annual fee payment |
Payment date: 20131127 Year of fee payment: 4 |
|
FPAY | Annual fee payment |
Payment date: 20140924 Year of fee payment: 5 |
|
FPAY | Annual fee payment |
Payment date: 20151007 Year of fee payment: 6 |
|
FPAY | Annual fee payment |
Payment date: 20161123 Year of fee payment: 7 |
|
FPAY | Annual fee payment |
Payment date: 20171122 Year of fee payment: 8 |
|
FPAY | Annual fee payment |
Payment date: 20181129 Year of fee payment: 9 |
|
FPAY | Annual fee payment |
Payment date: 20190923 Year of fee payment: 10 |